SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Tokyo hits record 10,000 COVID cases, Japan over 50,000 for first time

01/22/2022 | 04:29am EDT
FILE PHOTO: COVID-19 pandemic, in Tokyo

TOKYO (Reuters) -Tokyo recorded its fourth record number of daily COVID-19 infections on Saturday, breaking above 10,000, while Japan's exceeded 50,000 for the first time as the Omicron variant continues to spread rapidly.

The capital had 11,227 new coronavirus cases, the local government said a day after it reinstated curbs on mobility and business activity through Feb. 13.

Tokyo's case count, exceeding Friday's 9,699, were more than double the 4,561 logged a week earlier.

Three people in Tokyo died of COVID-19 and 12 were in serious condition on Saturday, the Tokyo government said.

Some 34.3% of hospital beds in the capital were being used by coronavirus patients. A rise in the occupancy rate to 50% would warrant a state of emergency with more severe restrictions, local officials have said.

Osaka prefecture announced 7,375 infections, a second consecutive record, and two deaths.

Infections nationwide totalled at least 50,200 as nearly 30 of Japan's 47 prefectures set records, broadcaster FNN reported.

As of Friday, 78.7% of Japan's population had been fully vaccinated, but only 1.5% had received a booster shot, according to the Prime Minister's Office.

The health ministry on Friday approved the use of the Pfizer vaccine for children aged five to 11 in an effort to ramp up the vaccination rate.

(Reporting by Kantaro Komiya; Editing by Raju Gopalakrishnan and William Mallard)

© Reuters 2022
All news about PFIZER, INC.
05/20Wall Street ends mixed after punishing week
05/20Rite Aid to Start Administering Pfizer's Booster Shot to Chidren Ages 5 to 11
05/20Pfizer Enters Deal to Sell COVID-19 Drug Paxlovid to Switzerland
05/20Pfizer's Xeljanz Recommended By European Medicines Agency Committee to Treat Ankylosing..
05/20Switzerland Secures Order for Pfizer's Antiviral COVID-19 Drug Paxlovid
05/20EU Member States Seek Changes To Supply Contracts For COVID-19 Jabs Amid Declining Dema..
05/19US Health Agency Approves Pfizer-BioNTech's COVID-19 Booster Jab For Children
05/19CDC urges Pfizer booster for children ages 5 to 11
05/19EU health regulator backs using AstraZeneca COVID shot as booster
05/19Thinking about trading options or stock in Tesla, Microsoft, Walt Disney, NVIDIA, or Pf..
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 10 478 M - -
P/E ratio 2022 8,75x
Yield 2022 3,09%
Capitalization 294 B 294 B -
EV / Sales 2022 2,73x
EV / Sales 2023 3,58x
Nbr of Employees 79 000
Free-Float 58,2%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 52,47 $
Average target price 57,79 $
Spread / Average Target 10,1%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-11.14%294 404
JOHNSON & JOHNSON3.45%465 705
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707
NOVO NORDISK A/S3.58%245 099